UNITED STATES
 SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM S-8

REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933
 
PURAMED BIOSCIENCE, INC.
(Exact name of registrant as specified in its charter)

Minnesota
 
20-5510104
(State or other jurisdiction of incorporation or organization)
 
(I.R.S. Employer Identification No.)

1326 Schofield Avenue
Schofield, Wisconsin 54476
 (Address of principal executive offices, including zip code)

PuraMed Bioscience, Inc. 2014 Incentive Stock and Award Plan
(Full title of the plan)

(715) 359-6373
(Telephone number, including area code, of agent for service)
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer
¨
 
Accelerated filer
¨
Non-accelerated filer
¨
 
Smaller reporting company
þ
 

 


 
 
 
 
 
CALCULATION OF REGISTRATION FEE

Title of securities
to be registered
 
Amount to be
Registered (1)
   
Proposed maximum offering price per share
   
Proposed maximum aggregate offering price
   
Amount of
registration fee (3)
 
                         
Common Shares, par value $0.001 per share
    75,000,000 (2)   $ 0.0024     $ 180,000     $ 23.22  

(1)
 
Pursuant to Rule 416 promulgated under the Securities Act of 1933, as amended, there are also registered hereunder such indeterminate number of additional shares as may be issued to the selling stockholders to prevent dilution resulting from stock splits, stock dividends or similar transactions.
   
(2)
Represent shares of common stock issuable pursuant to the PuraMed Bioscience, Inc. 2014 Incentive and Award Plan.
   
(3) Estimated solely for purposes of calculating the registration fee in accordance with Rule 457(c) under the Securities Act of 1933, using the average of the high and low price as reported on the OTC Markets on April 29, 2014 of $0.0024 per share.
 
 
 
2

 
 
PART I
Item 1.      Plan Information.

The documents containing the information specified in Item 1 will be sent or given to participants in the PuraMed Bioscience, Inc. 2014  Incentive and Award Plan (the “Plan”) as specified by Rule 428(b)(1) of the Securities Act of 1933, as amended (the "Securities Act"). Such documents are not required to be and are not filed with the Securities and Exchange Commission (the "Commision") either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424. These documents and the documents incorporated by reference in this Registration Statement pursuant to Item 3 of Part II of this Form S-8, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.
Item 2.      Registrant Information and Employee Plan Annual Information.

Upon written or oral request, any of the documents incorporated by reference in Item 3 of Part II of this Registration Statement (which documents are incorporated by reference in this Section 10(a) Prospectus), other documents required to be delivered to eligible employees, non-employee directors and consultants, pursuant to Rule 428(b) are available without charge by contacting:

Russell W. Mitchell
c/o Puramed Bioscience, Inc.
1326 Schofield Avenue
Schofield, Wisconsin 54476
(715) 359-6373
 
 
 
3

 
 
PART II

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

Item 3.      Incorporation of Documents by Reference.

The following documents filed by PuraMed Bioscience, Inc. (the “Registrant”) pursuant to the Securities Act and the Securities Exchange Act of 1934, as amended (the “Exchange Act”), respectively, are incorporated herein by reference:

(a)  
The Registrant’s Annual Report on Form 10-K for the fiscal year ended June 30, 2013, as filed with the Commission on October 15, 2013;

(b)  
The Registrant’s current reports on Form 8-K, as filed with the Commission on March 19, 2014, April 22, 2014 and April 30, 2014;

(c)  
The Registrant’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2013, as filed with the Commission on November 19, 2013; and

(d)  
The Registrant’s Quarterly Report on Form 10-Q for the quarter ended December 31, 2013, as filed with the Commission on February 19, 2014.
 
All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act after the date of this registration statement and prior to the filing of a post-effective amendment to this registration statement which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this registration statement and to be a part hereof from the date of filing of such documents.

Any statement contained in a document incorporated or deemed to be incorporated by reference into this registration statement shall be deemed to be modified or superseded for purposes of this registration statement to the extent that a statement contained in this registration statement or in any other subsequently filed document which also is or is deemed to be incorporated by reference into this registration statement modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this registration statement.

Nothing in this registration statement shall be deemed to incorporate information furnished but not filed with the Commission pursuant to Item 2.02 or Item 7.01 of Form 8-K.

Item 4.      Description of Securities.

We are authorized to issue 4,000,000,000 shares of stock which are designated common stock with par value of $0.001 per share and 100,000,000 shares of “blank check” Preferred Stock, par value $0.001 per share.

Holders of common stock are entitled to receive ratably such dividends, if any, as may be declared by the Board of Directors out of funds legally available. We have not paid any dividends since our inception, and we presently anticipate that all earnings, if any, will be retained for development of our business. Any future declaration of dividends will be at the discretion of our Board of Directors and will depend upon, among other things, our future earnings, operating and financial condition, capital requirements, and other factors.

Holders of our common stock have no preemptive rights or other subscription rights, conversion rights, redemption or sinking fund provisions. Upon our liquidation, dissolution or winding up, the holders of our common stock will be entitled to share ratably in the net assets legally available for distribution to shareholders after the payment of all of our debts and other liabilities. There are not any provisions in our Articles of Incorporation or our Bylaws that would prevent or delay change in our control.

 
4

 
 
Item 5.      Interests of Named Experts and Counsel.

The validity of the shares of common stock offered hereby will be passed upon for the Registrant by Naccarato & Associates (the “Firm”), 1100 Quail Street, Ste. 100, Newport Beach, California 92660.  Certain partners or employees of the Company’s outside counsel may be issued shares of common stock under the Plan from time to time in connection with payment for future legal services to be rendered pursuant to the terms of a written engagement agreement.  Neither the Firm, nor any of its partners or employees have or is to receive a substantial interest, direct or indirect, in the Registrant, nor are any of them connected with the Registrant other than in their role as outside legal counsel for the Registrant.

Item 6.      Indemnification of Directors and Officers.

Section 302A.521 of the Minnesota Statutes permits indemnification of directors, officers, employees and agents of a corporation under certain conditions and subject to certain limitations. Section 302A.521 empowers a corporation to indemnify any person who was or is a party or is threatened to be made a part to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that such person is or was a director, officer or agent of the corporation, subject to the statutory standards set forth therein.

Item 7.      Exemption from Registration Claimed.

Not applicable.

Item 8.      Exhibits.
INDEX TO EXHIBITS
 
Exhibit
Number
 
 
Exhibit
     
 
PuraMed Biosciences, Inc. 2014 Incentive and Award Plan*
     
 
Opinion of Naccarato & Associates*
     
 
Consent of Independent Registered Public Accounting Firm Tanner LLC*
     
23.2
 
Consent of Naccarato & Associates (contained in the Opinion filed as Exhibit 5.1).
     
24.1
 
Power of Attorney (contained on the signature pages hereto).

*Filed herewith

The exhibits filed herewith or incorporated by reference herein are set forth in the Exhibit Index filed as part of this registration statement.
 
 
5

 
 
Item 9. Undertakings.
 
(a)      The undersigned registrant hereby undertakes:
 
(1)      To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:
 
(i) To include any prospectus required by section 10(a)(3) of the Securities Act of 1933;
 
(ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) (§230.424(b) of this chapter) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement.
 
(iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;
 
Provided, however, That (A) Paragraphs (a)(1)(i) and (a)(1)(ii) of this section do not apply if the registration statement is on Form S–8 (§239.16b of this chapter), and the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to section 13 or section 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)) that are incorporated by reference in the registration statement.
 
(2) That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
 
(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
 
(b)      The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant's annual report pursuant to section 13(a) or section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan's annual report pursuant to section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
 
(h)      Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.
 
 
6

 
 
SIGNATURES

Signatures

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements of an amendment to a filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Schofield, Wisconsin, on May 2, 2014.
 
 
PURAMED BIOSCIENCE, INC.
 
       
 
By:
/s/  Russell Mitchell  
   
Russell Mitchell
 
   
Chief Executive Officer
 
       
 
Each person whose signature appears below hereby constitutes and appoints Russell Mitchell, his or her true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for him and in his name, place, and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) and additions to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, and hereby grants to such attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent or his substitute or substitutes may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirement of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates stated:
 
/s/ Russell Mitchell  
May 2, 2014
Russell Mitchell
   
Chief Executive Officer, Director
   


/s/ Charles Phillips  
May 2, 2014
Charles Phillips
   
Director
   


/s/ James Higgins  
May 2, 2014
James Higgins
   
Director
   

7